Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-000819-25
    Sponsor's Protocol Code Number:DS102A-05-AH1
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2018-12-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2018-000819-25
    A.3Full title of the trial
    A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis.
    Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-II-Studie zur Untersuchung der Wirksamkeit und Sicherheit von oral verabreichtem DS102 an Patienten mit schwerer akuter dekompensierter alkoholischer Hepatitis.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis.
    Wirksamkeit und Sicherheit von oral verabreichtem DS102 an Patienten mit schwerer akuter dekompensierter alkoholischer Hepatitis
    A.4.1Sponsor's protocol code numberDS102A-05-AH1
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03452540
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAfimmune
    B.1.3.4CountryIreland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAfimmune
    B.4.2CountryIreland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAfimmune
    B.5.2Functional name of contact pointRegulatory Affairs Department
    B.5.3 Address:
    B.5.3.1Street AddressTrintech Building, South County Business Park
    B.5.3.2Town/ cityLeopardstown, Dublin
    B.5.3.3Post code18
    B.5.3.4CountryIreland
    B.5.4Telephone number0035312946380
    B.5.5Fax number0035312176117
    B.5.6E-mailafimmune.regulatory@afimmune.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDS102 Capsule
    D.3.2Product code DS102
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNepeleuton
    D.3.9.1CAS number 1667760-39-5
    D.3.9.2Current sponsor codeDS102
    D.3.9.3Other descriptive name15(S)-HYDROXY-EICOSAPENTAENOIC ACID ETHYL ESTER
    D.3.9.4EV Substance CodeSUB193616
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Severe Acute Decompensated Alcoholic Hepatitis
    Schwere akute dekompensierte alkoholische Hepatitis
    E.1.1.1Medical condition in easily understood language
    Alcoholic Hepatitis
    Alkoholische Hepatitis
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10001624
    E.1.2Term Alcoholic hepatitis
    E.1.2System Organ Class 100000004871
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Efficacy Objective:
    • To compare the efficacy of orally administered DS102 capsules versus placebo, in the treatment of adult patients with severe acute decompensated Alcoholic Hepatitis (AH).
    Safety Objective:
    • To compare the safety of orally administered DS102 capsules versus placebo, in the treatment of adult patients with severe acute decompensated AH.
    Pharmacokinetic Objective:
    • To evaluate the pharmacokinetics (PK) of 15(S)-HEPE following orally administered DS102 capsules, in six adult patients with AH in the initial pilot phase of the study, followed by trough level assessment of 15(S)-HEPE in all study participants.
    Wirksamkeit:
    •Untersuchung der Wirksamkeit von oral verabreichten DS102-Kapseln im Vergleich zu Placebo bei der Behandlung von erwachsenen Patienten mit schwerer akut dekompensierter alkoholischer Hepatitis (AH).

    Sicherheit:
    •Untersuchung der Sicherheit von oral verabreichten DS102-Kapseln im Vergleich zu Placebo bei der Behandlung von erwachsenen Patienten mit schwerer akut dekompensierter alkoholischer Hepatitis (AH).

    Pharmakokinetik:
    •Untersuchung der Pharmakokinetik von 15(S)-HEPE nach oraler Verabreichung von DS102-Kapseln an sechs Patienten in der initialen Pilotphase der Studie, gefolgt von Talspiegelmessungen von 15(S)-HEPE bei allen Studienteilnehmern.
    E.2.2Secondary objectives of the trial
    N/A
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female patients aged 18 years and older.
    2. Total bilirubin of ≥ 5 mg/dl (85μmol/l).
    3. Patients with definite or probable AH.
    4. MELD ≥18 at baseline visit
    5. MDF ≥32 at baseline visit
    6. AST >50 U/L
    7. Aspartate aminotransferase/alanine aminotransferase
    (AST:ALT) ratio > 1.5
    8. Female patients, or female partners of male patients, of child
    bearing potential must use highly effective birth control
    methods or have a sterilised partner for the duration of the
    study. Highly effective birth control methods are defined as
    methods that can achieve a failure rate of less than 1% per
    year when used consistently and correctly. Such methods
    include intrauterine device or sexual abstinence.
    Note: A woman is considered of child bearing potential
    (WOCBP), i.e. fertile, following menarche and until becoming
    post-menopausal unless permanently sterile. Permanent
    sterilisation methods include hysterectomy, bilateral
    salpingectomy and bilateral oophorectomy.
    Note: Hormonal contraceptives are contraindicated in
    patients with severe hepatic diseases and are not acceptable
    as a birth control method in this study.
    Note: Sexual abstinence is considered a highly effective
    method only if defined as refraining from heterosexual
    intercourse during the entire period of risk associated with
    the study treatments. The reliability of sexual abstinence
    needs to be evaluated in relation to the duration of the
    clinical trial and the preferred and usual lifestyle of the
    subject.
    9. Patient and/or legally authorised representative must provide informed consent.
    10. Able to swallow the provided study medication.
    11. Not eligible for liver transplant during this hospitalisation.
    1.Männlich oder weiblich, im Alter von 18 Jahren oder darüber
    2.Gesamtbilirubin ≥ 5 mg/dl (85μmol/l)
    3.Patienten mit definitive oder wahrscheinlicher AH
    4.MELD ≥18 bei Baseline
    5.Maddrey DF ≥32 bei Baseline
    6.Aspartate aminotransferase (AST) >50 U/L
    7.Aspartate aminotransferase/alanine aminotransferase (AST:ALT) Ratio > 1.5
    8.Gebärfähige Patientinnen sowie gebärfähige Partnerinnen männlicher Patienten müssen während der Dauer der Studie hochwirksame Verhütungsmethoden anwenden, oder der Partner muss sterilisiert sein. Hochwirksame Verhütungsmethoden werden definiert als Methoden, deren Versagensrate bei dauerhafter und korrekter Anwendung niedriger als 1%/Jahr liegt. Zu diesen Methoden gehören intrauterin anzuwendende Methoden und sexuelle Abstinenz.
    Hinweis: Als gebärfähig werden Frauen eingestuft, die fruchtbar sind, bei denen die Menarche eingesetzt hat und die noch nicht post-menopausal sind, es sei denn, sie sind dauerhaft steril.
    Hinweis: Hormonelle Kontrazeptiva sind bei Patientinnen mit schweren Lebererkrankungen kontraindiziert und sind in dieser Studie nicht zulässig.
    Hinweis: Sexuelle Abstinenz wird nur dann als hochwirksame Verhütungsmethode eingestuft, wenn diese definiert ist als kontinuierliche Unterlassung heterosexuellen Verkehrs während der gesamten Dauer bestehender Risiken im Zusammenhang mit der Studienmedikation. Die Zuverlässigkeit sexueller Abstinenz muss im Vergleich zur Dauer der Studie mit dem bevorzugten und normalen Lebensstil der Betroffenen bewertet werden.
    9.Patientin/Patient oder ein Vormund müssen eine Einverständniserklärung unterzeichnen.
    10.Fähigkeit die Studienmedikation zu schlucken.
    11.Nicht qualifiziert für eine Lebertransplantation im Rahmen dieser stationären Behandlung.
    E.4Principal exclusion criteria
    1. Pregnant or lactating females.
    2. Spontaneous liver function improvement defined by decrease of bilirubin level and MDF of >10% within 5 days of hospital admission.
    3. Grade 4 hepatic encephalopathy (West Haven Criteria).
    4. Type 1 hepatorenal syndrome (HRS) or a serum creatinine >2 x ULN or the requirement for haemodialysis.
    5. History of hypersensitivity to any substance in DS102 capsules or placebo capsules.
    6. Alcohol abstinence of >6 weeks prior to screening.
    7. Duration of clinically apparent jaundice >3 months prior to baseline.
    8. Other causes of liver disease including:
    a. Evidence of chronic viral hepatitis (Hepatitis B DNA positive or HCV RNA positive).
    b. Biliary obstruction.
    c. Hepatocellular carcinoma.
    d. Wilsons disease.
    e. Budd Chiari Syndrome.
    f. Non-alcoholic fatty liver disease.
    9. History of or active non-liver malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas).
    10. Previous entry into the study.
    11. AST >400 U/L or ALT >270 U/L.
    12. Treatment with any experimental drug within 30 days prior to Day 0 visit (Baseline), or 5 half-lives (whichever is longer).
    13. Patients who have used dietary supplements rich in omega-3 oromega-6 fatty acids in the four weeks prior to baseline.
    14. Patients dependent on inotropic support (adrenaline or noradrenaline), including Terlipressin.
    15. Active variceal hemorrhage on this admission requiring more than 2 units of blood to maintain hemoglobin level within 48 hours
    16. Presence of refractory ascites.
    17. Untreated or unresolved sepsis.
    18. Patients with cerebral hemorrhage, extensive retinal hemorrhage, acute myocardial infarction (within last 6 weeks) or severe cardiac arrhythmias (not including atrial fibrillation).
    19. Known infection with HIV at screening.
    20. Significant systemic or major illnesses other than liver disease that, in the opinion of the investigator, would preclude or interfere with treatment with DS102 and/or adequate follow up.
    21. Previous liver transplantation.
    1. Schwangere oder stillende Frauen
    2. Spontane Verbesserung der Leberfunktion innerhalb von 5 Tagen nach Aufnahme in der Klinik, definiert durch die Abnahme des Bilirubins oder des MDF um >10%
    3. Hepatische Enzephalopathie Grad 4 (West Haven Criteria)
    4. Hepatorenales Syndrom Typ 1 (HRS) oder Serum Kreatinine >2 x ULN oder Notwendigkeit einer Haemodialyse
    5. Bekannte Überempfindlichkeit gegen eine der Substanzen in den DS102- oder Placebokapseln
    6. Alkoholabstinenz von >6 Wochen vor dem Screening
    7. Klinisch wahrscheinliche Gelbsucht mit einer Dauer >3 Monate vor dem Screening
    8. Andere Ursachen für eine Lebererkrankung einschließlich:
    a. Nachweis einer chronischen Virushepatitis (Hepatitis-B-DNA-positiv oder HCV-RNA-positiv)
    b. Gallenobstruktion
    c. Hepatozelluläres Karzinom
    d. Wilson-Krankheit
    e. Budd-Chiari-Syndrom
    f. Nicht alkoholische Fettleber
    9. Vorgeschichte oder aktive nicht an die Leber gebundener Malignome außer kurativ behandeltem Hautkrebs (Basalzell- oder Plaztenepithelkarzinome).
    10. Vorheriger Einschluss in die Studie
    11. AST >400 U/L oder ALT >270 U/L
    12. Behandlung mit einer anderen Studiensubstanz innerhalb von 30 Tagen vor Baseline oder 5 Halbwertzeiten (was auch immer länger ist),
    13. Patienten, die in den vier Wochen vor Baseline Nahrungsergänzungsmittel mit hohem Gehalt an Omega-3- oder Omega-6-Fettsäuren verwendet haben
    14. Patienten, die angewiesen sind auf inotrope Unterstützung (Adrenaline oder Noradrenalin), einschließlich Terlipressin
    15. Aktive Varizenblutung beim aktuellen Aufenthalt, die innerhalb von 48 Stunden mehr als 2 Einheiten Blut benötigt, um den Hämoglobinspiegel
    16. Vorhandensein von refraktärem Aszites
    17. Patienten mit bekannter Hirnblutung, ausgedehnten Netzhautblutungen, akutem Myokardinfarkt (innerhalb der letzten 6 Wochen) oder schwere Herzrhythmusstörungen (ohne Vorhofflimmern)
    19. Bekannte HIV-Infektion beim Screening
    20. Signifikante systemische oder schwerwiegende Krankheiten mit Ausnahme von Lebererkrankungen, die nach Ansicht des Prüfers die Behandlung mit DS102 und / oder eine angemessene Nachsorge ausschließen oder stören würden
    21. Erfolgte Lebertransplantation
    E.5 End points
    E.5.1Primary end point(s)
    Percentage change in MELD score from baseline to Day 28
    Veränderung des MELD Score in % zwischen Baseline und Tag 28
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 28
    Tag 28
    E.5.2Secondary end point(s)
    • Change in total bilirubin from baseline to Day 7, 14, 21 and 28
    •Proportion of patients showing a 25% reduction of bilirubin at day 7, 14, 21, and 28.
    •Change in serum cytokeratin 18-M30/M65 from baseline to Day 7, 14, 21 and 28
    •Change in AST levels from Baseline to Day 7, 14, 21 and 28
    •Change in AST:ALT ratio from Baseline to Day 7, 14, 21, 28
    •Change in MDF score from baseline to Day 7, 14, 21 and 28.
    •Proportion of patients showing a 25% reduction in MELD score from baseline to Day 7, 14, 21 and 28
    •Change in MELD score from baseline to Day 7, 14 and 21
    •Change in modified Sequential Organ Failure Assessment (m-SOFA) from baseline to Day 7, 14, 21 and 28
    •Proportion of patients with a 2-point worsening of m-SOFA from baseline to Day 7, 14, 21 and 28.
    •Change in hepatic encephalopathy as assessed by West Haven criteria, from baseline at Day 7, 14, 21 and 28
    •Incidence of acute kidney injury over 28 days (defined by requiring medicinal or mechanical support)
    •Incidence of variceal haemorrhage, ascites or
    hepatic encephalopathy over 28 days

    Exploratory Endpoints
    •Survival at day 7, 14, 21, 28 and 90 using Kaplan-Meier Plot
    •Change in Gamma Glutamyl Transferase (GT) from Baseline to Day 7, 14, 21 and 28
    •Change in ALT from Baseline to Day 7, 14, 21 and 28.
    •Change in Child Pugh score from baseline to Day 7, 14, 21 and 28
    •Change in APACHE-II score from baseline to Day 7, 14 and 28
    •Change in Lille score from baseline to Day 7, 14 and 28

    Safety Endpoints
    •Treatment emergent (S)AE and SUSARs
    •Veränderung des Gesamtbilirubin von Baseline zu Tag 7, 14, 21 und 28
    •Anteil der Patienten, die eine 25% Reduktion des Bilirubin aufweisen an den Tagen 7, 14, 21, und 28.
    •Veränderungen des Serum Cytokeratin 18-M30/M65 von Baseline bis Tag 7, 14, 21 und 28
    •Veränderung des AST-Levels von Baseline zu Tag 7, 14, 21 und 28
    •Veränderung der AST:ALT Ratio von Baseline zu Tag 7, 14, 21, 28
    •Veränderung des MDF-Score von Baseline zu Tag 7, 14, 21 und 28.
    •Anteil der Patienten, die eine 25%-Reduktion des MELD-Score aufweisen von Baseline zu Tag 7, 14, 21 und 28
    •Veränderung des MELD-Score von Baseline zu Tag 7, 14 und 21
    •Veränderung des m-SOFA von Baseline zu Tag 7, 14, 21 und 28
    •Anteil der Patienten, die eine Verschlechterung des m-SOFA um zwei Punkte von Baseline zu aufweisen Tag 7, 14, 21 und 28
    •Veränderung der hepatischen Enzephalopathie basierend auf den West Haven Kriterien, von Baseline zu aufweisen Tag 7, 14, 21 und 28
    •Inzidenz einer akuten Nierenerkrankung über 28 Tage (definiert über medikamentöse oder Gerätebehandlung)
    •Inzidenz von Varizenblutungen, Aszites oder hepatischer Enzephalopathie über 28 Tage

    Explorative Endpunkte
    •Überleben an den Tagen 7, 14, 21, 28 and 90 unter Nutzung des Kaplan-Meier Plot
    •Veränderung der Gamma Glutamyl Transferase (GT) von Baseline zu Tag 7, 14, 21 und 28
    •Veränderung der ALT von Baseline zu Tag 7, 14, 21 und 28
    •Veränderung des Child Pugh Score von Baseline zu Tag 7, 14, 21 und 28
    •Veränderung des APACHE-II Score von Baseline zu Tag 7, 14, 21 und 28
    •Veränderung des Lille Score von Baseline zu Tag 7, 14, 21 und 28

    Sicherheitsendpunkte:
    Behandlungsemergenz, (S)AEs und SUSARs
    E.5.2.1Timepoint(s) of evaluation of this end point
    Day 7, 14, 21 and 28
    Tag 7, 14, 21 und 28
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belarus
    Belgium
    France
    Georgia
    Germany
    Latvia
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of trial is defined as ‘last patient last visit (LPLV)’. LPLV is defined as the date the Investigator reviews the last subject’s safety data and determines that no further evaluation is required for the subject to complete the trial.
    Das Ende der Studie ist definiert als letzter Studienbesuch des letzten Patienten (LPLV). Der LPLV ist definiert als das Datum, an dem der Prüfarzt die Sicherheitsdaten des letzten Patienten kontrolliert und festlegt, dass keine weitere Untersuchung notwendig ist und der Patient die Studie beenden kann.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 101
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 25
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    If the patient is incapable of comprehending the nature, significance and implications of the clinical trial and of determining his/her will in the light of these facts , a legal custodian will be responsible for giving informed consent.
    Sollte ein Patient nicht in der Lage sein, Wesen, Bedeutung und Tragweite der klinischen Prüfung zu erkennen und seinen Willen hiernach auszurichten, wird die Einwilligung durch den gesetzlichen Vertreter oder Bevollmächtigten abgegeben.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 78
    F.4.2.2In the whole clinical trial 126
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Not different from expected normal treatment.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-12-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-03-25
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 06:06:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA